The scientific foundation for tobacco harm reduction, 2006-2011

Harm Reduction Journal

Volumn 8, Issue , 2011, Pages

  Rodu, Brad ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE;

ASSOCIATION; CANCER RISK; CARDIOVASCULAR RISK; CIGARETTE SMOKING; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HARM REDUCTION; HEALTH HAZARD; HEART INFARCTION; HUMAN; INFLAMMATORY DISEASE; MEDICAL LITERATURE; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; NORWAY; PARKINSON DISEASE; PREGNANCY COMPLICATION; PUBLIC HEALTH; REVIEW; SCIENTIFIC LITERATURE; SMOKELESS TOBACCO; SMOKING; STROKE; SWEDEN;

EID: 79960860218     PISSN: None     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/1477-7517-8-19     Document Type: Review

References (105)

1. Rodu B, Godshall WT. Tobacco harm reduction: an alternative cessation strategy for inveterate smokers. Harm Red J 2006, 3:37., http://www.harmreductionjournal.com/content/pdf/1477-7517-3-37.pdf
2. International Agency for Research on Cancer IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Smokeless tobacco and some tobacco-specific nitrosamines 2007, 89. Lyon, France, International Agency for Research on Cancer.
3. Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Lancet Oncol 2008, 9:667-675. 10.1016/S1470-2045(08)70173-6, 18598931.
4. Lee PN, Hamling J. Systematic review of the relation between smokeless tobacco and cancer in Europe and North America. BMC Medicine 2009, 7:36. 10.1186/1741-7015-7-36, 2744672, 19638245.
5. Lee PN, Hamling J. The relation between smokeless tobacco and cancer in Northern Europe and North America. A commentary on differences between the conclusions reached by two recent reviews. BMC Cancer 2009, 9:256. 10.1186/1471-2407-9-256, 3087330, 19638246.
6. Sponsiello-Wang Z, Weitkunat R, Lee PN. Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America. BMC Cancer 2008, 8:356. 10.1186/1471-2407-8-356, 2612688, 19046421.
7. Boffetta P, Aagnes B, Weiderpass E, Andersen A. Smokeless tobacco use and risk of cancer of the pancreas and other organs. Int J Cancer 2005, 114:992-995. 10.1002/ijc.20811, 15645430.
8. Luo J, Ye W, Zendehdel K, Adami J, Adami H-O, Boffetta P, Nyrén O. Oral use of Swedish moist snuff (snus) and risk of cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet 2007, 369:2015-2020. 10.1016/S0140-6736(07)60678-3, 17498797.
9. Lee PN. Summary of the epidemiological evidence relating snus to health. Regul Toxicol Pharmacol 2010,
10. Bertuccio P, La Vecchia C, Silverman DT, Petersen GM, Bracci PM, Negri E, Li D, Risch HA, Olson SH, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham ET, Bamlet WR, Holly EA, Lucenteforte E, Hassan M, Yu H, Kurtz RC, Cotterchio M, Su J, Maisonneuve P, Duell EJ, Bosetti C, Boffetta P. Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2011,
11. Heuch I, Kvåle G, Jacobsen BK, Bjelke E. Use of alcohol, tobacco, and coffee, and risk of pancreatic cancer. Br J Cancer 1983, 48:637-643. 10.1038/bjc.1983.245, 2011509, 6685527.
12. Rodu B, Cole P. A deficient study of smokeless tobacco use and cancer (letter). Int J Cancer 2006, 118:1585. 10.1002/ijc.21323, 16206262.
13. Rodu B. Snus and the risk of cancer of the mouth, lung, and pancreas. Lancet 2007, 370:1207. 10.1016/S0140-6736(07)61533-5, 17920914.
14. Bolinder G, Alfredsson L, Englund A, de Faire U. Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. Am J Public Health 1994, 84:399-404. 10.2105/AJPH.84.3.399, 1614817, 8129055.
15. Odenbro T, Bellocco R, Boffetta P, Lindelöf B, Adami J. Tobacco smoking, snuff dipping and the risk of cutaneous squamous cell carcinoma: a nationwide cohort study in Sweden. Br J Cancer 2005, 92:1326-1328. 10.1038/sj.bjc.6602475, 2361972, 15770206.
16. Odenbro T, Gillgren P, Bellocco R, Boffetta P, Håkansson N, Adami J. The risk for cutaneous malignant melanoma, melanoma in situ and intraocular malignant melanoma in relation to tobacco use and body mass index. Br J Dermatol 2007, 156:99-105. 10.1111/j.1365-2133.2006.07537.x, 17199574.
17. Fernberg P, Odenbro T, Bellocco R, Boffetta P, Pawitan Y, Zendehdel K, Adami J. Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: a nationwide cohort study in Sweden. Cancer Res 2007, 67:5983-5986. 10.1158/0008-5472.CAN-07-0274, 17575169.
18. Hergens M-P, Alfredsson L, Bolinder G, Lambe M, Pershagen G, Ye W. Long-term use of Swedish moist snuff and the risk of myocardial infarction amongst men. J Int Med 2007, 262:351-359.
19. Zendehdel K, Nyrén O, Luo J, Dickman PW, Boffetta P, Englund A, Ye W. Risk of gastroesophageal cancer among smokers and users of Scandinavian moist snuff. Int J Cancer 2008, 122:1095-1099.
20. Hergens M-P, Lambe M, Pershagen G, Terent A, Ye W. Smokeless tobacco and the risk of stroke. Epidemiol 2008, 19:794-799.
21. Hergens M-P, Lambe M, Pershagen G, Ye W. Risk of hypertension amongst Swedish male snuff users: a prospective study. J Int Med 2008, 264:187-194.
22. Carlens C, Hergens M-P, Grunewald J, Ekbom A, Eklund A, Höglund CO, Askling J. Smoking, use of moist snuff, and risk of chronic inflammatory diseases. Am J Resp Crit Care Med 2010, 181:1217-1222. 10.1164/rccm.200909-1338OC, 20203245.
23. Nordenvall C, Nilsson PJ, Ye W, Nyrén O. Smoking, snus use and risk of right- and left-sided colon, rectal and anal cancer: a 37-year follow-up study. Int J Cancer 2011, 128:157-165. 10.1002/ijc.25305, 20209500.
24. Lee PN. Circulatory disease and smokeless tobacco in Western populations: a review of the evidence. Int J Epidemiol 2007, 36:789-804. 10.1093/ije/dym039, 17591642.
25. Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ 2009, 339:b3060. 10.1136/bmj.b3060, 2728803, 19690343.
26. Henley SJ, Thun MJ, Connell C, Calle EE. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control 2005, 16:347-358. 10.1007/s10552-004-5519-6, 15953977.
27. Yatsuya H, Folsom AR. Risk of incident cardiovascular disease among users of smokeless tobacco in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2010, 172:600-605. 10.1093/aje/kwq191, 20688904.
28. Piano MR, Benowitz NL, FitzGerald GA, Corbridge S, Heath J, Hahn E, Pechacek TF, Howard G. Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment. A policy statement from the American Heart Association. Circulation 2010, 122:1520-1544. 10.1161/CIR.0b013e3181f432c3, 20837898.
29. Aro P, Ronkainen J, Storskrubb T, Vieth M, Engstrand L, Johansson SE, Bolling-Sternevald E, Bolinder G, Alving K, Talley NJ, Agréus L. Use of tobacco products and gastrointestinal morbidity: an endoscopic population-based study (the Kalixanda study). Eur J Epidemiol 2010, 25:741-750. 10.1007/s10654-010-9495-8, 20668918.
30. O'Reilly EJ, McCullough ML, Chao A, Henley SJ, Calle EE, Thun MJ, Ascherio A. Smokeless tobacco use and the risk of Parkinson's disease mortality. Mov Disord 2005, 20:1383-1384. 10.1002/mds.20587, 16007624.
31. Hedström AK, Basrnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009, 73:696-701. 10.1212/WNL.0b013e3181b59c40, 19720976.
32. , . Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health The health consequences of smoking: a report of the Surgeon General [Atlanta, Ga.]. 2004, Washington, D.C., Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
33. England LJ, Levine RJ, Mills JL, Klebanoff MA, Yu KF, Cnattingius S. Adverse pregnancy outcomes in snuff users. Am J Obstet Gynecol 2003, 189:939-943. 10.1067/S0002-9378(03)00661-6, 14586330.
34. Wikström AK, Cnattingius S, Galanti MR, Kieler H, Stephansson O. Effect of Swedish snuff (snus) on preterm birth. BJOG 2010, 117:1005-1010. 10.1111/j.1471-0528.2010.02575.x, 20465559.
35. Wikström AK, Cnattingius S, Stephansson O. Maternal use of Swedish snuff (snus) and risk of stillbirth. Epidemiol 2010, 21:772-778.
36. Heavner KK, Rosenberg Z, Phillips CV. Survey of smokers' reasons for not switching to safer sources of nicotine and their willingness to do so in the future. Harm Red J 2009, 6:14.
37. Peiper N, Stone R, van Zyl R, Rodu B. University faculty perceptions of the health risks related to cigarettes and smokeless tobacco. Drug Alcohol Rev 2010, 29:121-130. 10.1111/j.1465-3362.2009.00143.x, 20447218.
38. Wikmans T, Ramström L. Harm perception among Swedish daily smokers regarding nicotine, NRT-products and Swedish snus. Tobacco Induced Diseases 2010, 8:9. 10.1186/1617-9625-8-9, 2928193, 20707898.
39. Callery WE, Hammond D, O'Connor RJ, Fong GT. The appeal of smokeless tobacco products among young Canadian smokers: the impact of pictorial health warnings and relative risk messages. Nic Tob Res 2011,
40. Ramström L, Foulds J. Role of snus in initiation and cessation of tobacco smoking in Sweden. Tobacco Cont 2006, 15:210-214.
41. Furberg H, Lichtenstein P, Pedersen NL, Bulik CM, Lerman C, Sullivan PF. Snus use and other correlates of smoking cessation in the Swedish Twin Registry. Psycholog Med 2008, 38:1299-1308.
42. Gartner CE, Hall WD, Vos T, Bertram MY, Wallace AL, Lim SS. Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet 2007, 369:2010-2014. 10.1016/S0140-6736(07)60677-1, 17498798.
43. Rodu B, Cole P. Lung cancer mortality: comparing Sweden with other countries in the European Union. Scand J Public Health 2009, 37:481-486. 10.1177/1403494809105797, 19535408.
44. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) Health effects of smokeless tobacco products 2008, Health & Consumer Protection, Directorate-General, European Commission, Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR)., http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_013.pdf
45. Lund KE. A tobacco-free society or tobacco harm reduction? Which objective is best for the remaining smokers in Scandinavia?. SIRUS-Report no 6/2009, Norwegian Institute for Alcohol and Drug Research 2009, Oslo., http://hera.helsebiblioteket.no/hera/bitstream/10143/84913/1/sirusrap.6.09.eng.pdf
46. Lund KE, McNeill A, Scheffels J. The use of snus for quitting smoking compared with medicinal products. Nic Tob Res 2010, 12:817-822.
47. Lund KE, Scheffels J, McNeill A. The association between use of snus and quit rates for smoking: results from seven Norwegian cross-sectional studies. Addiction 2011, 106:162-197. 10.1111/j.1360-0443.2010.03122.x, 3021722, 20883459.
48. Tilashalski K, Rodu B, Cole P. A pilot study of smokeless tobacco in smoking cessation. Am J Med 1998, 104:456-458. 10.1016/S0002-9343(98)00085-0, 9626029.
49. Tilashalski K, Rodu B, Cole P. Seven year follow-up of smoking cessation with smokeless tobacco. J Pscyh Drugs 2005, 37:105-108.
50. Mendoza-Baumgart MI, Tulunay OE, Hecht SS, Zhang Y, Murphy S, Le C, Jensen J, Hatsukami DK. Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine. Nic Tob Res 2007, 12:1309-1323.
51. Sharp L, Johansson H, Fagerström K, Rutqvist LE. Smoking cessation among patients with head and neck cancer: cancer as a "teachable moment.". Europ J Cancer Care 2008, 17:114-119.
52. Tønnesen P, Mikkelsen K, Bremann L. Smoking cessation with smokeless tobacco and group therapy: an open, randomized, controlled trial. Nic Tob Res 2008, 10:1365-1372.
53. Caldwell B, Burgess C, Crane J. Randomized crossover trial of the acceptability of snus, nicotine gum, and Zonnic therapy for smoking reduction in heavy smokers. Nic Tob Res 2010, 12:179-183.
54. Carpenter MJ, Gray KM. A pilot randomized study of smokeless tobacco use among smokers not interested in quitting: changes in smoking behavior and readiness to quit. Nic Tob Res 2010, 12:136-143.
55. Cobb CO, Weaver MF, Eissenberg T. Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers. Tob Cont 2010, 19:367-373.
56. Kotlyar M, Hertsgaard LA, Lindgren BR, Jensen JA, Carmella SG, Stepanov I, Murphy SE, Hecht SS, Hatsukami DK. Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study. Cancer Epidemiol Biomarkers Prev 2011, 20:91-100. 10.1158/1055-9965.EPI-10-0349, 21068204.
57. Strat YL, Rehm J, Le Foll B. How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey. Tob Cont 2011, tc.2010.038703.
58. Barrett SP, Campbell ML, Temporale K, Good KBP. The acute effect of Swedish-style snus on cigarette craving and self-administration in male and female smokers. Hum Psychopharmacol 2011,
59. O'Connor RJ, Norton KJ, Bansal-Travers M, Mahoney MC, Cummings KM, Borland R. US smokers' reactions to a brief trial of oral nicotine products. Harm Red J 2011, 8:1., http://www.harmreductionjournal.com/content/8/1/1
60. Rodu B, Phillips CV. Switching to smokeless tobacco as a smoking cessation method: evidence from the 2000 National Health Interview Survey. Harm Red J 2008, 5:18., http://www.harmreductionjournal.com/content/pdf/1477-7517-5-18.pdf
61. Biener L, Bogen K. Receptivity to Taboka and Camel snus in a U.S. test market. Nic Tob Res 2009, 11:1154-1159.
62. Galanti MR, Rosendahl I, Wickholm S. The development of tobacco use in adolescence among "snus starters" and "cigarette starters": an analysis of the Swedish "BROMS" cohort. Nic Tob Res 2008, 10:315-323.
63. Tomar SL, Fox BJ, Severson HH. Is smokeless tobacco use an appropriate public health strategy for reducing societal harm from cigarette smoking?. Int J Environ Res Public Health 2009, 6:10-24. 2672338, 19440266.
64. Ary DV, Lichtenstein E, Severson HH. Smokeless tobacco use among male adolescents: patterns, correlates predictors and the use of other drugs. Prev Med 1987, 16:385-401. 10.1016/0091-7435(87)90039-9, 3588577.
65. Ary DV. Use of smokeless tobacco among male adolescents: concurrent and prospective relationships. National Cancer Institute Monograph 1989, 8:49-55.
66. Dent CW, Sussman S, Johnson CA, Hansen WB, Flay BR. Adolescent smokeless tobacco incidence: relationship with other drugs and psychosocial variables. Prev Med 1987, 16:422-431. 10.1016/0091-7435(87)90041-7, 3588579.
67. Glover ED, Laflin M, Edwards SW. Age of initiation and switching patterns between smokeless tobacco and cigarettes among college students in the United States. Am J Public Health 1989, 79:207-208. 10.2105/AJPH.79.2.207, 1349938, 2913845.
68. Tomar SL. Is use of smokeless tobacco a risk factor for cigarette smoking? The U.S. experience. Nic Tob Res 2003, 5:561-569.
69. Wetter DW, McClure JB, de Moor C, Cofta-Gunn L, Cummings S, Cinciripini PM, Gritz ER. Concomitant use of cigarettes and smokeless tobacco: prevalence, correlates, and predictors of tobacco cessation. Prev Med 2002, 34:638-648. 10.1006/pmed.2002.1032, 12052025.
70. Kozlowski LT, O'Connor, Edwards BQ, Flaherty BP. Most smokeless tobacco use is not a causal gateway to cigarettes: using order of product use to evaluate causation in a national U.S. sample. Addiction 2003, 98:1077-1085. 10.1046/j.1360-0443.2003.00460.x, 12873242.
71. Severson HH, Forrester KK, Biglan A. Use of smokeless tobacco is a risk factor for cigarette smoking. Nic Tob Res 2007, 9:1331-1337.
72. O'Connor RJ, Flaherty BP, Edwards BQ, Kozlowski LT. Regular smokeless tobacco use is not a reliable predictor of smoking onset when psychosocial predictors are included in the model. Nic Tob Res 2003, 5:535-543.
73. Timberlake DS, Huh J, Lakon CM. Use of propensity score matching in evaluating smokeless tobacco as a gateway to smoking. Nic Tob Res 2009, 11:455-462.
74. O'Connor RJ, Kozlowski LT, Flaherty BP, Edwards BQ. Most smokeless tobacco use does not cause cigarette smoking: results from the 2000 National Household Survey on Drug Abuse. Addict Behav 2005, 30:325-336. 10.1016/j.addbeh.2004.05.020, 15621403.
75. Rodu B, Cole P. Evidence against a gateway from smokeless tobacco use to smoking. Nic Tob Res 2010, 12:530-534.
76. Henningfield JE, Rose CA, Giovino GA. Brave new world of tobacco disease prevention: promoting dual tobacco-product use?. Am J Prev Med 2002, 23:226-228. 10.1016/S0749-3797(02)00502-0, 12350457.
77. Frost-Pineda K, Appleton S, Fisher M, Fox K, Gaworski CL. Does dual use jeopardize the potential role of smokeless tobacco in harm reduction?. Nic Tob Res 2010, 12:1055-1067.
78. Rodu B, Stegmayr B, Nasic S, Cole P, Asplund K. Evolving patterns of tobacco use in northern Sweden. J Int Med 2003, 253:660-665.
79. Rodu B. Dual use (letter). Nic Tob Res 2011,
80. United States District Court For the District of Columbia 2010, Civil Case No. 09-771. Memorandum Opinion by Richard. J. Leon, United States District Court For the District of Columbia., https://ecf.dcd.uscourts.gov/cgi-bin/show_public_doc?2009cv0771-54
81. Deyton LR, Woodcock J. Regulation of e-cigarettes and other tobacco products. 2011, U.S. Federal Drug Administration., http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm252360.htm
82. Mishori R. E-cigarettes: can they help you quit?. Parade Magazine 2009, http://www.parade.com/health/2009/07/12-e-cigarettes-healthy-or-not.html
83. Bergström M, Nordberg A, Lunell E, Antoni G, Långström B. Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography. Clin Pharmacol Ther 1995, 57:309-317. 10.1016/0009-9236(95)90156-6, 7697948.
84. Lunell E, Molander L, Leischow SJ, Fagerström K-O. Effect of nicotine vapour inhalation on the relief of tobacco withdrawal symptoms. Eur J Clin Pharmacol 1995, 48:235-240.
85. Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomized cross-over trial. Tob Cont 2010, 19:98-103.
86. Eissenberg T. Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration (letter). Tob Cont 2010, 19:87-88.
87. Vansickel AR, Cobb CO, Weaver MF, Eissenberg TE. A clinical laboratory model for evaluating the acute effects of electronic "cigarettes": nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomarkers Prev 2010, 19:1945-1953. 10.1158/1055-9965.EPI-10-0288, 2919621, 20647410.
88. Trtchounian A, Williams M, Talbot P. Conventional and electronic cigarettes (e-cigarettes) have different smoking characteristics. Nic Tob Res 2010,
89. Rose JE, Turner JE, Murugesan T, Behm FM, Laugesen M. Pulmonary delivery of nicotine pyruvate: sensory and pharmacokinetic characteristics. Exp Clin Psychopharmacol 2010, 18:385-394.
90. Laugesen M. Safety Report on the Ruyan® e-cigarette Cartridge and Inhaled Aerosol. 2008, Health New Zealand., http://www.healthnz.co.nz/RuyanCartridgeReport30-Oct-08.pdf
91. , . U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Evaluation of e-cigarettes. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research., http://www.fda.gov/downloads/Drugs/ScienceResearch/UCM173250.pdf
92. Osterdahl BG. The migration of tobacco-specific nitrosamines into the saliva of chewers of nicotine-containing chewing gum. Food Chem Toxicol 1990, 28:619-622. 10.1016/0278-6915(90)90169-N, 2272559.
93. Nilsson R. The molecular basis for induction of human cancers by tobacco specific nitrosamines. Reg Tox Pharmacol 2011, 60:268-280.
94. Wu J, Joza P, Sharifi M, Rickert WS, Lauterbach JH. Quantitative method for the analysis of tobacco-specific nitrosamines in cigarette tobacco and mainstream cigarette smoke by use of isotope dilution liquid chromatography tandem mass spectrometry. Anal Chem 2008, 80:1341-1345. 10.1021/ac702100c, 18189372.
95. Meister MA. Helping smokers quit: a role for smokeless tobacco?. 2006, American Council on Science and Health., http://www.acsh.org/publications/pubid.1403/pub_detail.asp
96. Laugesen M. Snuffing out cigarette sales and the smoking deaths epidemic. NZ Med J 2007, 120:U2587.
97. Gartner CE, Hall WD. Should the health community promote smokeless tobacco (snus) as a harm reduction measure? Smokers who switch to snus reduce their health risks. PLoS Medicine 4(7):e185.
98. Gartner CE, Hall WD. Should Australia lift the ban on low nitrosamine smokeless tobacco products?. Med J Austral 2008, 188:44-46.
99. Royal College of Physicians Harm reduction in nicotine addiction: helping people who can't quit. A report by the Tobacco Advisory Group of the Royal College of Physicians. 2007, London, United Kingdom, Royal College of Physicians., http://bookshop.rcplondon.ac.uk/details.aspx?e=234
100. Foulds J, Kozlowski L. Snus [smokeless tobacco] - what should the public-health response be?. Lancet 2007, 369:1976-1978. 10.1016/S0140-6736(07)60679-5, 17498796.
101. Britton J, Edwards R. Tobacco smoking, harm reduction, and nicotine product regulation. Lancet 2008, 371:441-445. 10.1016/S0140-6736(07)61482-2, 17920116.
102. , . U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Public Workshop: Risks and Benefits of Long-Term Use of Nicotine Replacement Therapy (NRT) Products. 2010, Arlington, VA, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research., http://www.fda.gov/Drugs/NewsEvents/ucm221185.htm
103. Healthy Lives, Healthy People: A Tobacco Control Plan for England. Tobacco Programme, Department of Health, United Kingdom 2011, London, UK SE1 8UG., http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_124917
104. Rodu B, Cole P. Nicotine maintenance for inveterate smokers. Technology 1999, 6:17-21.
105. Sweanor D, Alcabes P, Drucker E. Tobacco harm reduction: how rational public policy could transform a pandemic. Int J Drug Pol 2007, 18:70-74.